Treatment of functional dyspepsia

Current Treatment Options in Gastroenterology

Volumn 7, Issue 2, 2004, Pages 121-131

  Delgado Aros, Silvia ^a   Cremonini, Filippo ^a   Talley, Nicholas J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; AMOXICILLIN; ANTACID AGENT; ANTIDEPRESSANT AGENT; BISMUTH CITRATE; BISMUTH SALT; CHOLECYSTOKININ; CILANSETRON; CIMETIDINE; CISAPRIDE; CLARITHROMYCIN; DOMPERIDONE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; MISOPROSTOL; NITROIMIDAZOLE; NIZATIDINE; OMEPRAZOLE; PLACEBO; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RANITIDINE; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 ANTAGONIST; SEROTONIN ANTAGONIST; STOMACH SECRETION INHIBITOR; SUCRALFATE; TACHYKININ RECEPTOR ANTAGONIST; UNINDEXED DRUG;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DYSPEPSIA; ERADICATION THERAPY; EVIDENCE BASED MEDICINE; FECES COLOR; HEALTH CARE PLANNING; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HYPNOSIS; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; SAFETY; SIDE EFFECT;

EID: 3142712964     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-004-0033-1     Document Type: Review

References (53)

1. Talley NJ, Stanghellini V, Heading RC, et al.: Functional gastroduodenal disorders. Gut 1999, 45(suppl 2):37-42.
2. Kay L, Jorgensen T: Epidemiology of upper dyspepsia in a random population. Prevalence, incidence, natural history, and risk factors. Scand J Gastroenterol 1994, 29:2-6.
3. Frank L, Kleinman L, Ganoczy D, et al.: Upper gastrointestinal symptoms in North America: prevalence and relationship to healthcare utilization and quality of life. Dig Dis Sci 2000, 45:809-818.
4. Marsland DW, Wood M, Mayo F: Content of family practice. Part I. Rank order of diagnoses by frequency. Part II. Diagnoses by disease category and age/sex distribution. J Fam Pract 1976, 3:37-68.
5. Nyren O, Adami HO, Gustavsson S, et al.: Social and economic effects of non-ulcer dyspepsia. Scand J Gastroenterol 1985, 109(suppl):41-47.
6. Talley NJ, Silverstein MD, Agreus L, et al.: AGA technical review: evaluation of dyspepsia. American Gastroenterological Association. Gastroenterology 1998, 114:582-595.
7. Veldhuyzen van Zanten SJ, Flook N, Chiba N, et al.: An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. Can Med Assoc J 2000, 162(suppl 12):S3-S23.
8. Rauws EA, Tytgat GN: Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990, 335:1233-1235.
9. Laine L, Schoenfeld P, Fennerty MB: Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001, 134:361-369.
10. Moayyedi P, Soo S, Deeks J, et al.: Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2003, 1:CD002096.
11. Moayyedi P, Deeks J, Talley N, et al.: An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003, 98:2621-2626.
12. Moayyedi P, Soo S, Deeks J, et al.: Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ 2000, 321:659-664.
13. Nyren O, Adami HO, Bates S, et al.: Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Engl J Med 1986, 314:339-343.
14. Gotthard R, Bodemar G, Brodin U, et al.: Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol 1988, 23:7-18.
15. Moayyedi P, Soo S, Decks J, et al.: Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2003, 1:CD001960.
16. Bolling-Sternevald E, Lauritsen K, Aalykke C, et al.: Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 2002, 37:1395-1402.
17. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, et al.: Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001, 96:689-696.
18. Houghton LA, Calvert EL, Jackson NA, et al.: Visceral sensation and emotion: a study using hypnosis. Gut 2002, 51:701-704.
19. Brandt LJ, Bjorkman D, Fennerty MB, et al.: Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002, 97(suppl 11):7-26.
20. Creed F, Fernandes L, Guthrie E, et al.: The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003, 124:303-317.
21. Soo S, Moayyedi P, Decks J, et al.: Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2001, 4:CD002301.
22. Bates S, Sjoden PO, Nyren O: Behavioral treatment of non-ulcer dyspepsia. Scand J Behav Ther 1988, 17:155-165.
23. Hamilton J, Guthrie E, Creed F, et al.: A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000, 119:661-669.
24. Haug TT, Wilhelmsen I, Svebak S, et al.: Psychotherapy in functional dyspepsia. J Psychosom Res 1994, 38:735-744.
25. Management of dyspepsia: report of a working party. Lancet 1988, 1:576-579.
26. Talley NJ, Colin-Jones DG, Koch KL, et al.: Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 1991, 4:145-160.
27. Calvert EL, Houghton LA, Cooper P, et al.: Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002, 123:1778-1785.
28. Jackson JL, O'Malley PG, Tomkins G, et al.: Treatment of functional gastrointestinal disorders with anti-depressant medications: a meta-analysis. Am J Med 2000, 108:65-72.
29. Chial HJ, Camilleri M, Burton D, et al.: Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol 2003, 284:130-137.
30. Thompson Coon J, Ernst E: Systematic review: herbal medicinal products for non-ulcer dyspepsia. Aliment Pharmacol Ther 2002, 16:1689-1699.
31. Hills JM, Aaronson PI: The mechanism of action of peppermint oil on gastrointestinal smooth muscle. An analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology 1991, 101:55-65.
32. Saucier DM, Kavaliers M: Antagonistic effects of the selective, competitive N-methyl-D-aspartate (NMDA) receptor antagonist, NPC 12626, on kappa opiate-induced analgesia in male deer mice. Brain Res 1994, 637:292-296.
33. Kuiken SD, Lei A, Tytgat GN, et al.: Effect of the low-affinity noncompetitive N-methyl-d-aspartate receptor antagonist dextromethorphan on visceral perception in healthy volunteers. Aliment Pharmacol Ther 2002, 16:1955-1962.
34. Schmidt PT, Holst JJ: Tachykinins in regulation of gastric motility and secretion. Cell Mol Life Sci 2000, 57:579-588.
35. Kim DY, Camilleri M: Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000, 95:2698-2709.
36. Banner SE, Sanger GJ: Differences between 5-HT3 receptor antagonists in modulation of visceral hypersensitivity. Br J Pharmacol 1995, 114:558-562.
37. Cremonini F, Delgado-Aros S, Camilleri M: Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003, 15:79-86.
38. Talley NJ, Van Zanten SV, Saez LR, et al.: A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther 2001, 15:525-537.
39. Simonin F, Valverde O, Smadja C, et al.: Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. Embo J 1998, 17:886-897.
40. Dapoigny M, Abitbol JL, Fraitag B: Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig Dis Sci 1995, 40:2244-2249.
41. Delvaux M, Louvel D, Lagier E, et al.: The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999, 116:38-45.
42. Read NW, Abitbol JL, Bardhan KD, et al.: Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut 1997, 41:664-668.
43. Gottschlich R, Krug M, Barber A, et al.: kappa-Opioid activity of the four stereoisomers of the peripherally selective kappa-agonists, EMD 60,400 and EMD 61,753. Chirality 1994, 6:685-689.
44. Barber A, Bartoszyk GD, Bender HM, et al.: A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753. Br J Pharmacol 1994, 113:1317-1327.
45. Bender HM, Dasenbrock J: Brain concentrations of asimadoline in mice: the influence of coadministration of various P-glycoprotein substrates. Int J Clin Pharmacol Ther 1998, 36:76-79.
46. Burton MB, Gebhart GF: Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J Pharmacol Exp Ther 1998, 285:707-715.
47. Ozaki N, Sengupta JN, Gebhart GF: Differential effects of mu-, delta-, and kappa-opioid receptor agonists on mechanosensitive gastric vagal afferent fibers in the rat. J Neurophysiol 2000, 83:2209-2216.
48. Sengupta JN, Snider A, Su X, et al.: Effects of kappa opioids in the inflamed rat colon. Pain 1999, 79:175-185.
49. Delgado-Aros S, Chial HJ, Camilleri M, et al.: Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol 2003, 284:558-566.
50. Delgado-Aros S, Chial HJ, Cremonini F, et al.: Effects of asimadoline, a kappa-opioid agonist, on satiation and postprandial symptoms in health. Aliment Pharmacol Ther 2003, 18:507-514.
51. Smith GP, Tyrka A, Gibbs J: Type-A CCK receptors mediate the inhibition of food intake and activity by CCK-8 in 9- to 12-day-old rat pups. Pharmacol Biochem Behav 1991, 38:207-210.
52. Castillo EJ, Camilleri M, Burton DD, et al.: Effect of an oral CCK-A agonist, GI181771X, on gastric functions in healthy humans. Gastroenterology 2004, In press.
53. Feinle C, D'Amato M, Read NW: Cholecystokinin-A receptors modulate gastric sensory and motor responses to gastric distension and duodenal lipid. Gastroenterology 1996, 110:1379-1385.